A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms UNICAB
- 10 Apr 2019 Status changed from not yet recruiting to recruiting.
- 24 Mar 2019 Planned End Date changed from 30 Jan 2024 to 30 Apr 2024.
- 24 Mar 2019 Planned primary completion date changed from 30 Jan 2022 to 30 Apr 2022.